Channel Medsystems Brings Women New, Minimally Invasive Alternative Treatment with AcuityAI
AcuityMD enables successful re-launch of Cerene Endometrial Cryotherapy platform to provide a better option for the 1
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
AcuityMD, the AI platform trusted by over 500 MedTech companies, today announced its partnership with Channel Medsystems, a medical technology (medtech) company dedicated to transforming women’s healthcare globally to commercially relaunch Cerene Endometrial Cryotherapy. Cerene is a non-hormonal, incision-free endometrial cryotherapy treatment designed to reduce heavy menstrual bleeding (menorrhagia), which affects one in five or 10 million women in the U.S.
Despite developing a minimally invasive, in-office treatment for heavy menstrual bleeding and dysmenorrhea, Channel Medsystems faced surprisingly low engagement among targeted physicians at launch. The company re-analyzed market data and discovered it was targeting the wrong group of healthcare providers, doctors focused strictly on treating the condition with heat-based ablation therapy. Channel Medsystems endometrial cryotherapy was being incorrectly compared to the 25-year-old ablation approach, with a declining user base. Channel Medsystems leveraged AcuityAI to successfully pivot its commercial strategy and relaunch Cerene.
“We scrubbed the word ‘ablation’ from everything, and completely rebranded all commercial materials to focus strictly on the differentiators and advantages of cryotherapy. It’s a different technology that preserves access to the uterine cavity,” explained Tara Murphy, Channel Medsystems Vice President of Marketing. “And we leaned into AcuityAI to help us identify the right target physicians, prioritize markets with the largest opportunity, and strategically expand our field team with better customer segmentation.”
Channel Medsystems implemented the new, data-driven commercial strategy and quickly experienced sizable increases in new accounts, re-order rates, and quarter over quarter growth.
“Since relaunching Cerene using AcuityMD’s AI platform to develop a refreshed customer segmentation strategy, we have made meaningful progress increasing physician engagement and building awareness of a differentiated treatment option for women suffering from heavy menstrual bleeding and dysmenorrhea,” added Murphy. “Our progress continues with AcuityMD’s Salesforce integration as we can easily import target lists into Salesforce as leads.”
Notably, with the addition of prescription data in AcuityAI, Channel Medsystems will now be able to find a subset of women suffering with heavy periods who are prescribed birth control as a treatment yet both the patients and their prescribers may not be aware of Channel Medsystems’ non-hormonal treatment option. With AcuityAI, the company can quickly see who is prescribing birth control and begin to understand if they are a potential Cerene candidate.
Channel Medsystems has also partially credited AcuityAI data for recent funding as it leveraged the solution to demonstrate its commercial pathway to investors. And, as a result, the company announced it reached $30 million in its ongoing Series C funding in August 2026. “AcuityMD provided the right data to validate and back our claims to investors and instill confidence for our future success,” concluded Murphy. “We showed investors that we are making decisions guided by industry-specific data, and that all came from AcuityMD.”
Learn about how AcuityMD is empowering MedTech organizations like Channel Medsystems at HLTH 2026 in Las Vegas. Join AcuityMD on Tuesday, Nov 17 at 1:50 pm at the Insights Stage, where executives will discuss how to drive innovations to patients faster using AI.
About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide a safe, effective and convenient therapy for women suffering from heavy menstrual bleeding without the need for general anesthesia. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access and empowering women with greater control over their care. For more information, please visit Cerene.com.
About AcuityMD
AcuityMD is the AI platform for MedTech trusted by over 500 MedTech companies – including 16 of the top 20. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117623665/en/
Media gallery
